Latest news with #BcellLymphoma
Health Line
04-07-2025
- Health
- Health Line
What Are the Different Types of Non-Hodgkin's Lymphoma?
Key takeaways Non-Hodgkin's lymphoma includes various types, classified based on the cells they originate from. The main categories are B-cell lymphomas, T-cell lymphomas, and NK cell lymphomas. Different types have distinct characteristics and treatment approaches. They can also have different growth rates (aggressive or indolent). Aggressive NHLs, like diffuse large B-cell lymphoma (DLBCL), are fast-growing but often respond well to treatment, while indolent lymphomas, such as follicular lymphoma, progress slowly and can be difficult to cure. Understanding the specific type of lymphoma is crucial for determining the best treatment plan. Individual outlooks vary widely based on the specific lymphoma type, stage, and other factors like age and genetics. Lymphoma is a group of cancers that develop in white blood cells called lymphocytes. These white blood cells consist of: T cells B cells natural killer (NK) cells What is non-Hodgkin's lymphoma? Non-Hodgkin's lymphoma (NHL) describes one group of cancers that affect lymphocytes. These cancers share some common characteristics that separate them from Hodgkin's lymphoma, another type. The World Health Organization (WHO) divides NHL into more than 60 subtypes depending on: the types of cells affected how the cells look under a microscope certain genetic changes NHLs are broadly categorized into B-cell lymphomas and T-cell and NK-cell lymphomas. Doctors may also characterize them as aggressive (fast-growing) and indolent (slow-growing). Learn about the causes of non-Hodgkin's lymphoma. B-cell lymphomas make up 85–90% of cases of NHL. In this article, we examine common types of NHL and what distinguishes them from one another. Aggressive NHL are lymphomas that are fast-growing and fast-moving. About 60% of NHLs are aggressive, according to the Leukemia and Lymphoma Society. Aggressive B-cell lymphomas Aggressive B-cell lymphomas start in the B cells. Types of aggressive B-cell lymphomas can include: Diffuse large B-cell lymphoma (DLBCL): DLBCL is the most common type of lymphoma and makes up about one-third of all cases of NHL. It tends to develop quickly but often responds to treatment: About 75% of people having no signs of this cancer after treatment. Mantle cell lymphoma: This type makes up 5% of NHLs. Mantle cell lymphoma can grow slowly or quickly but has usually already spread throughout the body by the time it's diagnosed. Lymphoblastic lymphoma: Lymphoblastic lymphoma makes up 2% of NHLs. It can develop from B cells or T cells. It has a similar treatment to acute lymphoblastic leukemia (ALL). Burkitt lymphoma: In the United States, this type of lymphoma is associated with a past infection with the Epstein-Barr virus, which is the virus that causes infectious mononucleosis. It may also occur in people who take immunosuppressant medications. Less common types of aggressive B-cell lymphomas can include: Indolent B-cell lymphomas Indolent NHL are lymphomas that are slow-growing and chronic. About 40% of NHLs are indolent. Indolent B-cell lymphomas can include: Follicular lymphoma: Follicular lymphoma is the second most common form of NHL. It makes up 1 in 5 lymphomas in the United States. Follicular lymphoma tends to progress slowly. It often responds to treatment but can be difficult to cure. Treatment can range from watching and waiting to radiation therapy, chemotherapy, and immunotherapy. Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): CLL and SLL are essentially the same disease. If most of the cancer cells are in your bloodstream and bone marrow, it's called CLL. When most cancer cells are found in your lymph nodes, it's called SLL. Marginal zone lymphoma: Marginal zone lymphoma is a group of slow-growing lymphomas that arise in B cells that look small under a microscope. They make up roughly 8% of NHL cases. Mucosa-associated lymphoid tissue (MALT) lymphoma: MALT is the most common subtype of marginal zone lymphoma. Doctors categorize it further based on its location. Waldenström macroglobulinemia or lymphoplasmacytic lymphoma: Cancer cells in this type of rare cancer resemble both plasma cells and lymphocytes. Hairy cell leukemia: Despite the name, this slow-growing cancer affects B lymphocytes. T-cell and NK-cell lymphomas Aggressive T-cell and NK-cell lymphomas start in the T and natural killer (NK) cells. Types can include: Peripheral T-cell lymphoma (PTCL): Peripheral T-cell lymphoma is a group of lymphomas that develop in T cells and NK cells. 'Peripheral' means it arises in lymph tissue outside your bone marrow. They make up between 5 and 15% of NHLs in Western countries and may require high dose chemotherapy and a stem cell transplant. Angioimmunoblastic T-cell lymphoma (AITL): This is a subtype of PTCL. Systemic anaplastic large cell lymphoma (ALCL): ALCL is a rare type of NHL, making up only 1% of cases. Lymphoblastic lymphoma: This type can develop from B or T cells. Cutaneous T-cell lymphoma (CTCL): This type starts in the skin. More rare types can include: hepatosplenic T-cell lymphoma enteropathy-associated intestinal T-cell lymphoma extranodal natural killer/T-cell lymphoma (ENK/TCL), nasal type adult T-cell leukemia/lymphoma What is the survival rate of non-Hodgkin's lymphoma? The overall 5-year survival rate for all types of NHL is about 74%. This number is based on data from people who received a diagnosis between 2013 and 2019. An individual's outlook with NHL depends on the particular type of lymphoma they have, as survival rates can vary widely by type and cancer stage. Factors that affect a person's outlook can include: their age and overall health cancer stage and how far it has spread factors in the genetics of the tumor how the cancer responds to treatment the blood level of lactate dehydrogenase (LDH), which goes up with the amount of lymphoma in the body Frequently asked questions How many types of non-Hodgkin's lymphoma are there? There are more than 60 types of NHL. What is the most common subtype of non-Hodgkin's lymphoma? The most common subtype of NHL is diffuse large B-cell lymphoma (DLBCL). This type makes up about one-third of all NHL diagnoses. What are the two main groups of non-Hodgkin's lymphoma? Doctors typically categorize NHL by the cell type, as either B-cell lymphomas or T-cell and NK-cell lymphomas. Doctors may also categorize them as aggressive (fast-growing) or indolent (slow-growing). Takeaway NHL can be broadly categorized as B-cell lymphomas or T-cell and NK-cell lymphomas, or by aggressive and indolent NHL. Most types of NHL affect your B cells. The symptoms of many types of lymphoma are similar. They're usually impossible to differentiate without lab tests analyzing your blood and bone marrow cells.
Globe and Mail
02-07-2025
- Health
- Globe and Mail
B-cell Non-hodgkin Lymphoma Clinical Trials, Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis
"B-cell Non-hodgkin Lymphoma Pipeline Insights" DelveInsight's, 'B-Cell Non-Hodgkin Lymphoma - Pipeline Insight, 2025' report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in B-Cell Non-Hodgkin Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. According to DelveInsight, over 75 major companies are actively engaged in the development of more than 80 treatment therapies for B-cell non-Hodgkin lymphoma. B-cell Non-hodgkin Lymphoma Overview: B-cell non-Hodgkin lymphoma (NHL) is a type of cancer that arises from abnormal B lymphocytes—white blood cells essential to the immune system. It accounts for over 85% of all NHL cases, making it the most common subtype. B-cell NHL includes several subtypes, classified based on cell morphology, surface proteins, and genetic traits. Key subtypes include diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and Burkitt lymphoma. The disease typically starts in the lymph nodes or lymphoid tissues and can spread to other organs, such as the gastrointestinal tract. Common symptoms include painless swollen lymph nodes, fever, night sweats, fatigue, weight loss, itchy skin, and pain in the chest, abdomen, or bones. When fever, night sweats, and weight loss occur together, they are known as B symptoms and are important for staging and prognosis. Diagnosing B-cell NHL—especially types with small- to medium-sized cells—can be difficult due to their resemblance to reactive lymphadenopathy and other lymphomas. Accurate diagnosis relies on a combination of techniques, including immunohistochemistry and flow cytometry, which must be interpreted in the context of the patient's clinical presentation and cellular morphology. Proper recognition of cytologic features is key to choosing the right diagnostic tests. Subtypes such as marginal zone lymphoma, follicular lymphoma, mantle cell lymphoma, CLL/SLL, and lymphoplasmacytic lymphoma are often misdiagnosed based on cytology alone. Therefore, a lymph node biopsy is usually necessary for definitive diagnosis and proper classification. "B-cell Non-hodgkin Lymphoma Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the B-cell Non-hodgkin Lymphoma Therapeutics Market. Key Takeaways from the B-cell Non-hodgkin Lymphoma Pipeline Report DelveInsight's B-cell Non-hodgkin Lymphoma pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for B-cell Non-hodgkin Lymphoma treatment. In May 2023, Bristol Myers Squibb announced positive topline results from two studies: TRANSCEND FL, a global, multicenter Phase 2 study evaluating Breyanzi (lisocabtagene maraleucel) in patients with relapsed or refractory follicular lymphoma (FL), and TRANSCEND NHL 001, a pivotal Phase 1 study assessing Breyanzi in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL), including mantle cell lymphoma (MCL). Both studies met the primary endpoint of overall response rate, with Breyanzi showing statistically significant and clinically meaningful responses in relapsed or refractory FL and MCL. In May 2023, Janssen Biotech, a subsidiary of Johnson & Johnson, announced a global collaboration and licensing agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture, and commercialize next-generation CAR T-cell therapies for treating B-cell malignancies. In May 2023, Genmab A/S revealed that the FDA approved EPKINLY™ (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from indolent lymphoma, after two or more lines of systemic therapy. In January 2023, Fate Therapeutics, Inc. announced it had declined a proposal from Janssen Biotech to continue their collaboration and option agreement under revised terms, leading to the termination of the agreement and the winding down of all collaboration activities in the first quarter of 2023. Key B-cell Non-hodgkin Lymphoma companies such as Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy, Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics, and others are evaluating new drugs for B-cell Non-hodgkin Lymphoma to improve the treatment landscape. Promising B-cell Non-hodgkin Lymphoma pipeline therapies in various stages of development include Valemetostat, MB-106, CB-010, LP-284, and others. B-cell Non-hodgkin Lymphoma Pipeline Analysis The report provides insights into: The report provides detailed insights into the key companies that are developing therapies in the B-cell Non-hodgkin Lymphoma Market. The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for B-cell Non-hodgkin Lymphoma treatment. It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the B-cell Non-hodgkin Lymphoma market. Download our free sample page report on B-cell Non-hodgkin Lymphoma pipeline insights B-cell Non-hodgkin Lymphoma Emerging Drugs Valemetostat: Daiichi Sankyo MB-106: Mustang Bio CB-010: Caribou Biosciences LP-284: Lantern Pharma B-cell Non-hodgkin Lymphoma Companies Over 75 key companies are working on developing therapies for B-cell non-Hodgkin lymphoma. Among them, Daiichi Sankyo has drug candidates for B-cell non-Hodgkin lymphoma in the advanced Phase II stage. DelveInsight's report covers around 22+ products under different phases of clinical development like Late stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) along with the details of Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates B-cell Non-hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intravenous Subcutaneous Oral Intramuscular B-cell Non-hodgkin Lymphoma Products have been categorized under various Molecule types such as Monoclonal antibody Small molecule Peptide Download Sample Pages to Get an in-depth Assessment of the Emerging B-cell Non-hodgkin Lymphoma Therapies and Key Companies: B-cell Non-hodgkin Lymphoma Clinical Trials and advancements B-cell Non-hodgkin Lymphoma Pipeline Therapeutic Assessment • B-cell Non-hodgkin Lymphoma Assessment by Product Type • B-cell Non-hodgkin Lymphoma By Stage • B-cell Non-hodgkin Lymphoma Assessment by Route of Administration • B-cell Non-hodgkin Lymphoma Assessment by Molecule Type Download B-cell Non-hodgkin Lymphoma Sample report to know in detail about the B-cell Non-hodgkin Lymphoma treatment market @ B-cell Non-hodgkin Lymphoma Therapeutic Assessment Table of Content 1. Report Introduction 2. Executive Summary 3. B-cell Non-hodgkin Lymphoma Current Treatment Patterns 4. B-cell Non-hodgkin Lymphoma - DelveInsight's Analytical Perspective 5. Therapeutic Assessment 6. B-cell Non-hodgkin Lymphoma Late-Stage Products (Phase-III) 7. B-cell Non-hodgkin Lymphoma Mid-Stage Products (Phase-II) 8. Early Stage Products (Phase-I) 9. Pre-clinical Products and Discovery Stage Products 10. Inactive Products 11. Dormant Products 12. B-cell Non-hodgkin Lymphoma Discontinued Products 13. B-cell Non-hodgkin Lymphoma Product Profiles 14. B-cell Non-hodgkin Lymphoma Key Companies 15. B-cell Non-hodgkin Lymphoma Key Products 16. Dormant and Discontinued Products 17. B-cell Non-hodgkin Lymphoma Unmet Needs 18. B-cell Non-hodgkin Lymphoma Future Perspectives 19. B-cell Non-hodgkin Lymphoma Analyst Review 20. Appendix 21. Report Methodology Request the Sample PDF to Get Detailed Insights About the B-cell Non-hodgkin Lymphoma Pipeline Reports Offerings Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Kritika Rehani Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
Yahoo
16-06-2025
- Business
- Yahoo
AbelZeta Announces Promising Long-Term Outcomes for C-CAR039, a Novel CD19/CD20 Bi-Specific CAR-T Therapy, in Patients with R/R B NHL at EHA 2025
MILAN, June 16, 2025 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on discovery and development of innovative and proprietary cell-based therapeutic products, presented promising four-year clinical outcomes from 48 relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) patients treated with C-CAR039 (also known as Prizloncabtagene Autoleucel) in greater China, at the European Hematology Association (EHA) 2025 Congress. The study evaluated the safety and efficacy of C-CAR039, a novel anti-CD19/CD20 bi-specific CAR-T therapy. The dual-targeting approach to both CD20 and CD19 antigens aims to enhance therapeutic efficacy and reduce the likelihood of antigen escape, a common mechanism of resistance in B-cell malignancies. Key Findings: The overall response rate (ORR) and complete response (CR) rate were 91.5% and 85.1%, respectively for all patients Among the 43 LBCL pts, ORR and CR were 90.7% and 86.0%, respectively With a median follow-up of 45.5 months (range, 3.1–62.8), the median duration of response (DOR), progression-free survival (PFS), and overall survival (OS) were not reached KM estimates of 48-m PFS rate are 52.5% for all patients and 53.4% for LBCL patients, respectively KM estimates of 48-m OS rate are 65.4% for all patients and 66.7% for LBCL patients, respectively Safety Highlights: CRS of any grade: 93.8% | Grade ≥3: 2.1% ICANS of any grade: 6.3% | No severe cases (Grade ≥3) reported No new safety signals were observed with longer follow-up C-CAR039 has continued to show an excellent safety profile and deep and durable responses in R/R B-NHL patients, especially in those with R/R LBCL. These results continue to provide strong support for the curative potential of C-CAR039 as a next-generation therapy for R/R B-NHL. Late-stage clinical development is ongoing. "The long-term clinical outcomes data for C-CAR039 are highly encouraging, demonstrating sustained responses in patients with relapsed or refractory B-cell non-Hodgkin lymphoma," said Tony (Bizuo) Liu, Chairman and Chief Executive Officer of AbelZeta. "These results underscore our commitment and corporate goal to develop transformative therapies that address significant unmet medical needs in cancer." Dr. Yihong Yao, Chief Scientific Officer of AbelZeta, commented, "The strong clinical results of C-CAR039 demonstrate the added value of targeting CD20 in addition to CD19 in aggressive B-NHL. By addressing the limitations of single-antigen therapies - such as CD19 antigen escape - C-CAR039 enables deeper tissue penetration and more complete B-cell depletion. The durable responses observed support the continued advancement of C-CAR039 as a promising new treatment for patients with aggressive B-cell malignancies." For more information on the study and access to the poster presentation, please visit the EHA Library poster here. AbelZeta previously presented 30-month Phase 1 clinical trial results at the 65th American Society of Hematology (ASH) Annual Meeting in December 2023, through oral presentation #1025, as well as at EHA 2024, through poster presentation #P1475. The data with 30 months follow up was published in Blood 2025 Apr 3;145(14):1526-1535. AbelZeta Inc. (formerly known as Cellular Biomedicine Group, Inc.), entered into a worldwide collaboration and licensing agreement with Johnson & Johnson* in 2023 to develop and commercialize next-generation CAR-T cell therapies (excluding Greater China). The Phase 1 study for C-CAR039 was conducted by AbelZeta in China for the treatment of patients with B-cell non-Hodgkin lymphoma. Johnson & Johnson is evaluating the safety and efficacy of this asset (known as JNJ-90014496 outside of Greater China) through a separate study involving a global patient population. Phase 1b data for JNJ-90014496 were presented at EHA 2025 on Friday, June 13, informing the recommended Phase 2 dose and an initial assessment of safety, efficacy and pharmacokinetics in R/R LBCL patients. For more information, please visit Johnson and Johnson website: *The legal entity to the worldwide collaboration and license agreement is Janssen Biotech, Inc., a Johnson & Johnson company. About AbelZeta Pharma, is a global clinical-stage biopharmaceutical company with centers of excellence in Rockville, Maryland and Shanghai, China. AbelZeta is focusing on developing innovative and proprietary cell-based therapeutic products and is committed to ushering in bespoke treatments that harness the body's own immune system to fight against hematological malignancies and solid tumors, as well as inflammatory and immunological diseases. AbelZeta advances research and development in its own GMP facilities at its centers of excellence for early-stage clinical studies, with a pipeline comprised of CAR-T therapies. Forward-Looking StatementsStatements in this communication relating to plans, strategies, specific activities, and other statements that are not descriptions of historical facts are forward-looking statements. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include any risks detailed from time to time in the Company's reports. Such statements are based on the management's current beliefs and expectations and are subject to significant risks and uncertainties outside of management and the Company's control. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as otherwise required by law, the Company does not undertake any obligation, and expressly disclaims any obligation, to update, alter or otherwise revise any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise. Company Contact:Sarah KellyDirector of CommunicationsAbelZeta Pharma, Inc.+1 (240) 552 View original content to download multimedia: SOURCE AbelZeta Pharma, Inc.
ABC News
02-06-2025
- General
- ABC News
Cough leads Sunshine Coast woman to rare Burkitt lymphoma diagnosis
Childhood educator Jessie Stott knew something was not right when she could not shake an aggressive cough for more than three months. Ms Stott, 33, had always led an active and healthy lifestyle. The Nirimba resident, on Queensland's Sunshine Coast, trained at a gym five days a week, ate a balanced diet, and had no family history of cancer. She enjoyed her job and was studying nursing. She and her high-school sweetheart partner, 37-year-old carpenter Lucas Vogelpoel, were even trying for a baby. But her persistent cough would not go away. "Doctors kept saying it was a viral infection, but then it kept getting worse," Ms Stott said. After months of pushing for answers, her doctor ordered a CT scan in March. It revealed an 80-millimetre growth on her chest — the size of an orange. She was referred to a surgeon in April but wait times were more than two months. With the growth pressing on her heart, no diagnosis, and still no real answers, Ms Stott's symptoms worsened. Then in early May, late on a Friday night, she woke up unable to breathe and with a "tingly" left arm. "I thought I was having a heart attack," Ms Stott said. She was rushed to Sunshine Coast University Hospital. After advocating for herself again while in hospital, Ms Stott received a diagnosis. It was B-cell lymphoma. Just a few weeks later she was told the mass had grown by another 20 centimetres. A biopsy confirmed it was Burkitt lymphoma, an aggressive form of cancer requiring immediate and intensive chemotherapy. Burkitt lymphoma is extremely rare and known for rapidly expanding. Ms Stott has since been undergoing intensive chemotherapy. "We were booked in for an IVF cycle, which we had to forgo," Ms Stott said. Mr Vogelpoel said it was heartbreaking to give up the IVF. "But her health is more important," he said. Ms Stott has four months of exhausting treatment ahead of her, involving 21-day chemotherapy cycles with a seven-day break in between. She also has three lumbar punctures a week, where medical staff jab a needle into her spine to remove fluid, then inject her with chemotherapy. "It's very painful," Ms Stott said. General practitioner Katie Gardner, who is also clinical editor at Country to Coast Queensland, said it could be worth following up with a doctor if flu-like symptoms lasted longer than a week. "Australians generally report high satisfaction with their GPs," she said. "But if you feel your concerns aren't being heard or taken seriously, the first step is to raise them directly with your treating doctor, especially if you've noticed a pattern over time or worsening symptoms. She said people who were still concerned could ask whether further tests or a referral might be appropriate, seek a second opinion from another GP, or call 13 HEALTH (13 43 25 84). "You know your body best," she said. "If something doesn't feel right, it's OK to keep asking questions or request additional follow-up." Ms Stott said pushing doctors for answers saved her life. "If I didn't keep pushing I'd still be waiting for a diagnosis," she said. "Most people don't get to hospital until it's too late and their airways are closing. "People know their own bodies and if you feel like something isn't right, just keep pushing."
